Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL203775 | 0.86 | ALDH1A1 (0.60) | ALDH1A1HPGDPTGDR2MAPTMEN1 | |
| SCHEMBL1398786 | 0.85 | GAA (0.57) | ALDH1A1HPGDPTGDR2ALOX5MAPT | |
| SCHEMBL13494115 | 0.84 | RXRA (0.45) | ALDH1A1HPGDMAPTKMT2ALMNA | |
| SCHEMBL7051370 | 0.84 | ALOX5 (0.54) | ALDH1A1HPGDPTGDR2ALOX5MAPT | |
| SCHEMBL5524292 | 0.84 | GAA (0.49) | ALDH1A1HPGDMEN1KMT2AGAA | |
| SCHEMBL13494131 | 0.84 | RARA (0.54) | ALDH1A1HPGDPTGDR2MAPTMEN1 | |
| SCHEMBL275863 | 0.83 | NTRK1 (0.59) | ALDH1A1HPGDALOX5KMT2APTGS2 | |
| SCHEMBL1339569 | 0.83 | PTGS2 (0.54) | ALDH1A1PTGDR2ALOX5KMT2APTGS2 | |
| SCHEMBL1398715 | 0.83 | PTGDR2 (0.62) | ALDH1A1PTGDR2MAPTMEN1KMT2A | |
| SCHEMBL4786383 | 0.82 | DHODH (0.62) | ALDH1A1HPGDMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994336-B2 | Azetidine compounds as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-09 | — | — | US | disclosed |
| EP-2069332-B1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-02 | — | — | EP | disclosed |
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
| EP-2069332-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008087611-A2 | PYRROLIDINE- AND PIPERIDINE- BIS-AMIDE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008020405-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | ALDH1A1 1961/4885HPGD 1787/4885PTGDR2 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.